Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack In Vitro
Nicolas A. Geis, S. Zell, R. Rutz, et al.
Current Cancer Drug Targets (2010) Vol. 10, Iss. 8, pp. 922-931
Closed Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Complement in cancer: untangling an intricate relationship
Edimara S. Reis, Dimitrios C. Mastellos, Daniel Ricklin, et al.
Nature reviews. Immunology (2017) Vol. 18, Iss. 1, pp. 5-18
Open Access | Times Cited: 352
Complement regulators as novel targets for anti-cancer therapy: A comprehensive review
Ruchi Saxena, Elizabeth B. Gottlin, Michael J. Campa, et al.
Seminars in Immunology (2025) Vol. 77, pp. 101931-101931
Closed Access | Times Cited: 2
The Role of Complement in Tumor Growth
Rubén Pı́o, Leticia Corrales, John D. Lambris
Advances in experimental medicine and biology (2013), pp. 229-262
Open Access | Times Cited: 191
Progress and Trends in Complement Therapeutics
Daniel Ricklin, John D. Lambris
Advances in experimental medicine and biology (2012), pp. 1-22
Open Access | Times Cited: 111
The complement system in cancer: Ambivalence between tumour destruction and promotion
Srinivas Mamidi, Simon Höne, Michael Kirschfink
Immunobiology (2015) Vol. 222, Iss. 1, pp. 45-54
Closed Access | Times Cited: 109
Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer
Saskia Meyer, Jeanette H.W. Leusen, Péter Boross
mAbs (2014) Vol. 6, Iss. 5, pp. 1133-1144
Open Access | Times Cited: 100
Beyond the Role of CD55 as a Complement Component
So Hee Dho, Jae Cheong Lim, Lark Kyun Kim
Immune Network (2018) Vol. 18, Iss. 1
Open Access | Times Cited: 92
Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies
Ronald P. Taylor, Margaret A. Lindorfer
Seminars in Immunology (2016) Vol. 28, Iss. 3, pp. 309-316
Closed Access | Times Cited: 87
Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab
Srinivas Mamidi, Marc Cinci, Max Hasmann, et al.
Molecular Oncology (2013) Vol. 7, Iss. 3, pp. 580-594
Open Access | Times Cited: 99
Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention
Zvi Fishelson, Michael Kirschfink
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 69
Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity
Kirstine Lavrsen, Caroline B. Madsen, Morten G. Rasch, et al.
Glycoconjugate Journal (2012) Vol. 30, Iss. 3, pp. 227-236
Closed Access | Times Cited: 73
Complement in Cancer and Cancer Immunotherapy
Martin Kolev, Laurence Towner, Rossen Donev
Archivum Immunologiae et Therapiae Experimentalis (2011) Vol. 59, Iss. 6, pp. 407-419
Open Access | Times Cited: 63
The dual role of complement in cancer and its implication in anti-tumor therapy
Ioannis Kourtzelis, Stavros Rafail
Annals of Translational Medicine (2016) Vol. 4, Iss. 14, pp. 265-265
Open Access | Times Cited: 48
CD46 and Oncologic Interactions: Friendly Fire against Cancer
Michelle Elvington, M. Kathryn Liszewski, John P. Atkinson
Antibodies (2020) Vol. 9, Iss. 4, pp. 59-59
Open Access | Times Cited: 43
“Complimenting the Complement”: Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma
Astha Malik, Unmesha Thanekar, Surya Amarachintha, et al.
Frontiers in Oncology (2021) Vol. 10
Open Access | Times Cited: 36
CD55 in cancer: Complementing functions in a non-canonical manner
Rashmi Bharti, Goutam Dey, Feng Lin, et al.
Cancer Letters (2022) Vol. 551, pp. 215935-215935
Open Access | Times Cited: 26
CD46 processing: A means of expression
Siobhán Ní Choileáin, Anne Astier
Immunobiology (2011) Vol. 217, Iss. 2, pp. 169-175
Open Access | Times Cited: 54
Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells
Srinivas Mamidi, Simon Höne, Claudia Teufel, et al.
OncoImmunology (2015) Vol. 4, Iss. 3, pp. e979688-e979688
Open Access | Times Cited: 38
Anti-HER2 cancer-specific mAb, H2Mab-250-hG<sub>1</sub> possesses higher complement-dependent cytotoxicity than trastuzumab
Hiroyuki Suzuki, Tomokazu Ohishi, Tomohiro Tanaka, et al.
(2024)
Open Access | Times Cited: 3
Anti-HER2 Cancer-Specific mAb, H2Mab-250-hG1, Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab
Hiroyuki Suzuki, Tomokazu Ohishi, Tomohiro Tanaka, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8386-8386
Open Access | Times Cited: 3
Harnessing machine learning and multi-omics to explore tumor evolutionary characteristics and the role of AMOTL1 in prostate cancer
Weian Zhu, Jianjie Wu, Wenjie Lai, et al.
International Journal of Biological Macromolecules (2024) Vol. 286, pp. 138402-138402
Closed Access | Times Cited: 3
Immunohistochemical Expression and Prognostic Value of CD97 and Its Ligand CD55 in Primary Gallbladder Carcinoma
Jinsheng Wu, Lei Liu, Shaochuang Wang, et al.
Journal of Biomedicine and Biotechnology (2012) Vol. 2012, pp. 1-7
Open Access | Times Cited: 37
Germline variation in complement genes and event‐free survival in follicular and diffuse large B‐cell lymphoma
Bridget Charbonneau, Matthew J. Maurer, Zachary S. Fredericksen, et al.
American Journal of Hematology (2012) Vol. 87, Iss. 9, pp. 880-885
Open Access | Times Cited: 37
CD59 is overexpressed in human lung cancer and regulates apoptosis of human lung cancer cells
Baijun Li, Hui Lin, Jian Fan, et al.
International Journal of Oncology (2013) Vol. 43, Iss. 3, pp. 850-858
Open Access | Times Cited: 31
The effects of CD59 gene as a target gene on breast cancer cells
Bing Li, Xianming Chu, Meihua Gao, et al.
Cellular Immunology (2011) Vol. 272, Iss. 1, pp. 61-70
Closed Access | Times Cited: 26
Page 1 - Next Page

Scroll to top